Denali Therapeutics Inc. (NASDAQ: DNLI) stock closed at 36.23 per share at the end of the most recent trading day (a -3.67% change compared to the prior day closing price) with a volume of 458.82K shares and market capitalization of 4.47B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 291 people. Denali Therapeutics Inc. CEO is Ryan J. Watts.

The one-year performance of Denali Therapeutics Inc. stock is -27.39%, while year-to-date (YTD) performance is -18.77%. DNLI stock has a five-year performance of %. Its 52-week range is between 20.24 and 56.8, which gives DNLI stock a 52-week price range ratio of 43.74%

Denali Therapeutics Inc. currently has a PE ratio of -16.40, a price-to-book (PB) ratio of 5.31, a price-to-sale (PS) ratio of 41.27, a price to cashflow ratio of 10.60, a PEG ratio of 2.32, a ROA of -20.26%, a ROC of -27.82% and a ROE of -29.01%. The company’s profit margin is 7.75%, its EBITDA margin is -251.00%, and its revenue ttm is $112.42 Million , which makes it $0.91 revenue per share.

Of the last four earnings reports from Denali Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.51 for the next earnings report. Denali Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Denali Therapeutics Inc. is Strong Buy (1.38), with a target price of $67.91, which is +87.44% compared to the current price. The earnings rating for Denali Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Denali Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Denali Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.54, ATR14 : 1.93, CCI20 : 82.89, Chaikin Money Flow : -0.02, MACD : 1.56, Money Flow Index : 51.68, ROC : 5.44, RSI : 54.29, STOCH (14,3) : 73.71, STOCH RSI : 0.54, UO : 61.03, Williams %R : -26.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Denali Therapeutics Inc. in the last 12-months were: Alexander O. Schuth (Option Excercise at a value of $12 301), Alexander O. Schuth (Sold 99 232 shares of value $4 831 679 ), Carole Ho (Sold 17 351 shares of value $770 918 ), Marc Tessier-Lavigne (Sold 92 431 shares of value $3 724 373 ), Ryan J. Watts (Option Excercise at a value of $399 984), Ryan J. Watts (Sold 74 592 shares of value $3 432 921 ), Steve E. Krognes (Option Excercise at a value of $42 500), Steve E. Krognes (Sold 16 732 shares of value $699 422 ), Vicki L. Sato (Sold 6 664 shares of value $346 474 )